Clinical Scorecard: Tumor Regression Induced by Belzutifan in a Case of Sporadic Hemangioblastoma: A Review of the Literature
At a Glance
Category
Detail
Condition
Sporadic and VHL-associated central nervous system hemangioblastomas (HBs)
Key Mechanisms
HIF-2α accumulation due to VHL inactivation leads to tumorigenesis; belzutifan selectively inhibits HIF-2α to suppress oncogenic transcription
Target Population
Patients with CNS hemangioblastomas, including those with VHL disease and sporadic cases
Care Setting
Neurosurgical and oncology settings with access to targeted systemic therapies
Key Highlights
Hemangioblastomas are WHO grade 1, vascular-rich CNS tumors occurring sporadically or with VHL disease.
Belzutifan, a selective HIF-2α inhibitor, received FDA approval for VHL-associated neoplasms including CNS HBs.
First reported case of tumor regression in sporadic HB treated with belzutifan suggests HIF-2α pathway dependence beyond VHL mutations.
Guideline-Based Recommendations
Diagnosis
MRI imaging to identify tumor location and characteristics.
Histopathological confirmation following surgical resection.
Genetic testing for VHL alterations in suspected cases.
Management
Surgical gross total resection (GTR) is primary treatment for cranial HBs.
Stereotactic radiosurgery (SRS) for inaccessible, residual, or recurrent tumors.
Consider belzutifan for VHL-associated HBs; emerging evidence supports use in sporadic cases.
Monitoring & Follow-up
Serial MRI to assess tumor response and progression.
Clinical monitoring for neurological symptoms and treatment side effects.
Risks
Surgical risks include cranial nerve injury due to tumor vascularity and adherence.
Potential for tumor progression despite radiosurgery.
Limited data on long-term safety and efficacy of belzutifan in sporadic HBs.
Patient & Prescribing Data
Patients with VHL-associated CNS hemangioblastomas and emerging use in sporadic HBs
Belzutifan administered orally at 120 mg/day demonstrated objective response rates of 44–76% and disease control rates up to 90% in CNS HBs; tolerability is favorable with durable responses.
Clinical Best Practices
Prioritize surgical resection when feasible for symptomatic or growing hemangioblastomas.
Utilize stereotactic radiosurgery for residual or inoperable lesions.
Incorporate genetic testing to guide targeted therapy decisions.
Consider belzutifan therapy in VHL-associated HBs and evaluate potential in sporadic cases with HIF-2α pathway involvement.
Monitor patients closely with serial imaging and neurological assessments.
by Rebekka E. Hooks, Niket Yadav, Mark Willy L. Mondia, Georgios Mantziaris, Alaa Saleh, Anna Vi Jones, Matthew McCord, Melike Mut, Ashok R. Asthagiri, Benjamin W. Purow
